|
FY2025
12 months to Sep 30, 2025
|
FY2024
12 months to Sep 30, 2024
|
FY2023
12 months to Sep 30, 2023
|
FY2022
12 months to Sep 30, 2022
|
FY2021
12 months to Sep 30, 2021
|
|
|---|---|---|---|---|---|
| OPERATING ACTIVITIES | |||||
| Net income | |||||
| Adjustments to reconcile net loss to net cash used in operating activities: | |||||
| Depreciation and amortization | |||||
| Impairment of intangible assets | |||||
| Provision for credit losses | |||||
| Gain on sale of ENTADFI® assets | |||||
| Loss on sale of FC2 business | |||||
| Noncash change in right-of-use assets | |||||
| Noncash interest expense, net of interest paid | |||||
| Gain on extinguishment of debt | |||||
| Share-based compensation | |||||
| Deferred income taxes | |||||
| Provision for obsolete inventory | |||||
| Change in fair value of derivative liabilities | |||||
| Change in fair value of equity securities | |||||
| Loss on disposal of fixed assets | |||||
| Other | |||||
| Changes in operating assets and liabilities: | |||||
| (Increase) decrease in accounts receivable | |||||
| Decrease in inventories | |||||
| Decrease in prepaid expenses and other assets | |||||
| Decrease in accounts payable | |||||
| (Decrease) increase in accrued expenses and other current liabilities | |||||
| Decrease in operating lease liabilities | |||||
| Net cash used in operating activities | |||||
| INVESTING ACTIVITIES | |||||
| Proceeds from sale of FC2 business, net of costs | |||||
| Cash proceeds from sale of ENTADFI® assets | |||||
| Proceeds from sale of equity securities | |||||
| Capital expenditures | |||||
| Net cash provided by investing activities | |||||
| FINANCING ACTIVITIES | |||||
| Payment on extinguishment of residual royalty agreement liabilities | |||||
| Payment of deferred equity financing issuance costs | |||||
| Jefferies Sales Agreement | |||||
| Total payment of deferred equity financing issuance costs | |||||
| Proceeds from premium finance agreement | |||||
| Proceeds from stock option exercises | |||||
| Installment payments on premium finance agreement | |||||
| Net cash (used in) provided by financing activities | |||||
| Net (decrease) increase in cash, cash equivalents, and restricted cash | |||||
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT BEGINNING OF YEAR | |||||
| CASH, CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR | |||||
| Supplemental disclosure of cash flow information: | |||||
| Cash paid for income taxes | |||||
| Cash paid for interest | |||||
| Schedule of non-cash investing and financing activities: | |||||
| Equity securities received from sale of ENTADFI® assets | |||||
| Shares issued in connection with common stock purchase agreement | |||||
| Amortization of deferred costs related to common stock purchase agreement | |||||
| Jefferies Sales Agreement | |||||
| Total amortization of deferred costs related to common stock purchase agreement | |||||
| Right-of-use assets recorded in exchange for lease liabilities | |||||
Loading...